| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/26/2009 | CA2689141A1 Radiolabelled fluorobenzamide analogues, their synthesis and use in diagnostic imaging |
| 02/25/2009 | EP2028278A1 RNA sequence-specific mediators of RNA interference |
| 02/25/2009 | EP2028276A1 Method for production of acetic acid bacterium-type ceramide |
| 02/25/2009 | EP2028274A2 An antisense oligonucleotide against the TGF-beta2 gene |
| 02/25/2009 | EP2028190A1 Compounds and methods for therapy and diagnosis of lung cancer |
| 02/25/2009 | EP2028187A1 Human and mouse targeting peptides identified by phage display |
| 02/25/2009 | EP2028186A2 Hepatitis C inhibitor tri-peptides |
| 02/25/2009 | EP2028182A1 Cysteine protease inhibitors |
| 02/25/2009 | EP2028180A1 Novel aminopyridine derivatives as mGluR5 antagonists |
| 02/25/2009 | EP2027878A1 Injection device filled with local anaesthetic for on-the-spot therapy for insect bites for anyone |
| 02/25/2009 | EP2027864A1 Composition for improvement of lipid metabolism |
| 02/25/2009 | EP2027863A1 Intestinal eosinophil-suppressing composition |
| 02/25/2009 | EP2027862A1 Composition for enhancing immune function |
| 02/25/2009 | EP2027861A1 Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of Huntington's didease |
| 02/25/2009 | EP2027860A1 The use of nicotine, analogues thereof, precursors thereof or derivatives thereof in the treatment of various pathological processes capable of improvement with alpha-msh administered in prophylactic or therapeutic form |
| 02/25/2009 | EP2027859A1 Anhydrous compositions for increasing blood flow |
| 02/25/2009 | EP2027858A1 Methods for attaining enhanced sexual wellness using anhydrous compositions |
| 02/25/2009 | EP2027857A2 Anhydrous compositions useful for attaining enhanced sexual wellness |
| 02/25/2009 | EP2027856A1 Method of treating or preventing central nervous system disorders with compounds having selectivity benzodiazepine receptor |
| 02/25/2009 | EP2027855A1 Use of gestagens in combination with (6S)5-methyl tetrahydro folate for endometriosis therapy with simultaneous reduction of the side effects of therapy and reduction in the risk of congenital deformities for with the onset of pregnancy |
| 02/25/2009 | EP2027854A1 Analgesic uses of norketamine and ketamine/norketamine prodrugs |
| 02/25/2009 | EP2027853A2 Kinase inhibitors for treating cancers |
| 02/25/2009 | EP2027851A1 Topical pharmaceutical formulations and methods of treatment |
| 02/25/2009 | EP2027850A1 Pharmaceutical compositions containing voriconazole |
| 02/25/2009 | EP2027783A1 Functional food composition that is rich in phenolic compounds and use of said composition |
| 02/25/2009 | EP2027143A2 Compounds and compositions as channel activating protease inhibitors |
| 02/25/2009 | EP2027141A1 11beta-benzaldoxime derivatives of d-homooestra-4,9-dien-3-ones |
| 02/25/2009 | EP2027139A1 Crystalline a and b forms of a maleate salt of 5-amino-3- (2 ', 3 '-di-o-acetyl-beta-d-ribofuranosyl) -3h-thiazolo [4, 5-d]pyrimidin-2-one |
| 02/25/2009 | EP2027136A1 Large-particle cyclodextrin inclusion complexes and methods of preparing same |
| 02/25/2009 | EP2027132A1 Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists |
| 02/25/2009 | EP2027131A1 39-desmethoxy-39-methyl derivatives of rapamycin. |
| 02/25/2009 | EP2027130A1 36 -des (3 -methoxy-4 -hydroxycyclohexyl) 36 - (3 -hydroxycycloheptyl) derivatives of rapamycin for the treatment of cancer and other disorders |
| 02/25/2009 | EP2027129A2 Fused heterocylic compounds and their use as mglur5 modulators |
| 02/25/2009 | EP2027128A2 Fused heterocylic compounds and their use as mglur5 modulators |
| 02/25/2009 | EP2027127A1 Pyrazolo [1, 5-a]pyrimidines as cdk inhibitors |
| 02/25/2009 | EP2027126A2 Crystalline forms of 5-chloro-6- (2, 6-difluoro-4-[3- (methylamino) propoxy] phenyl)-n-((1s)-2, 2, 2,-trifluoro-1-methylethyl][1,2,4]triazolo [1,5-a]pyrimidin-7-amine salts |
| 02/25/2009 | EP2027125A1 Pentacyclic indole derivatives as antiviral agents |
| 02/25/2009 | EP2027124A1 Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| 02/25/2009 | EP2027123A2 Compounds and compositions as protein kinase inhibitors |
| 02/25/2009 | EP2027122A1 Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use |
| 02/25/2009 | EP2027121A1 Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 02/25/2009 | EP2027120A2 Mglur5 modulators i |
| 02/25/2009 | EP2027119A2 Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| 02/25/2009 | EP2027118A2 Polymorphs of (r)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-thione hydrochloride |
| 02/25/2009 | EP2027115A1 Dioxaspiroketal derivatives, process for their preparation and uses thereof |
| 02/25/2009 | EP2027114A1 Maleate co-crystal of azd1152 |
| 02/25/2009 | EP2027113A1 Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
| 02/25/2009 | EP2027112A2 Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
| 02/25/2009 | EP2027111A2 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
| 02/25/2009 | EP2027110A2 Mglur5 modulators iii |
| 02/25/2009 | EP2027109A1 4- (2, 6-dichloro-benzoylamino) -1h-pyrazole-s-carboxylic acid (1-methanesulph0nyl-piperidin-4-yl) -amide for the treatment of cancer |
| 02/25/2009 | EP2027108A1 Histamine receptor antagonists comprising an azepin core |
| 02/25/2009 | EP2027107A1 2, 4 -diamino pyrimidines as cell cycle kinase inhibitors |
| 02/25/2009 | EP2027105A2 Novel process for preparing intermediates of ccr antagonists |
| 02/25/2009 | EP2027104A1 Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors |
| 02/25/2009 | EP2027103A1 New chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof |
| 02/25/2009 | EP2027098A1 1-(2-aryl-2-oxoethyl)-3-phenyl-1, 4-diazaspiro (4.5)dec-3-en-2-one derivatives and their use as glycine transporter inhibitors |
| 02/25/2009 | EP2027096A1 Substituted arylimidaz0l0ne and triaz0l0ne as inhibitors of vasopressin receptors |
| 02/25/2009 | EP2027092A1 Optical enantiomers of phenyramidol and process for chiral synthesis |
| 02/25/2009 | EP2027091A1 New pharmaceutical compounds |
| 02/25/2009 | EP2027089A1 Impurities of donepezil |
| 02/25/2009 | EP2027086A2 N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists |
| 02/25/2009 | EP2027085A1 Prostaglandin ep4 agonists |
| 02/25/2009 | EP2027082A1 12-aryl or heteroaryl prostaglandin analogs |
| 02/25/2009 | EP2027081A2 Therapeutic prostaglandin compounds for the treatment of glaucoma |
| 02/25/2009 | EP2026835A1 Nasal and buccal compositions for controlling snoring |
| 02/25/2009 | EP2026832A2 Cladribine regimen for treating multiple sclerosis |
| 02/25/2009 | EP2026831A2 Methods and compositions for treating and preventing peripheral nerve damage |
| 02/25/2009 | EP2026828A1 Use of at least one polyphenol for promoting eye health |
| 02/25/2009 | EP2026825A2 Furanone-initiated polymers |
| 02/25/2009 | EP2026821A1 Hyaluronic acid binary mixtures and therapeutic use thereof |
| 02/25/2009 | EP2026820A1 Compositions comprising chitin microparticles and their medical uses |
| 02/25/2009 | EP2026819A1 Prevention and/or treatment of neurodegenerative disorders |
| 02/25/2009 | EP2026817A1 Use of drospirenone for preventing high blood pressure in prehypertensive patients |
| 02/25/2009 | EP2026816A2 Treprostinil administration using a metered dose inhaler |
| 02/25/2009 | EP2026815A1 Controlled released preparations of oxcarbazepine having sigmoidal release profile |
| 02/25/2009 | EP2026814A2 Mirtazapine for the treatment of neuropathic pain |
| 02/25/2009 | EP2026813A2 5 ht receptor mediated neurogenesis |
| 02/25/2009 | EP2026812A1 Use of 1,7-dimethylxanthine for the manufacture of a non-anxiogenic psychoanaleptic drug for the treatment of a neuropsychiatric disorder |
| 02/25/2009 | EP2026811A1 Pyrazolo [3, 4-d]pyrimidine derivatives useful to treat respiratory disorders |
| 02/25/2009 | EP2026810A2 Compositions and methods for modulating the immune system |
| 02/25/2009 | EP2026809A2 Reversion of malignant phenotype with 9-hydroxy ellipticine derivatives |
| 02/25/2009 | EP2026808A1 Combination therapy for the treatment of cancer |
| 02/25/2009 | EP2026807A1 Use of parasympatholytic substances to enhance and accelerate stem cell differentiation, related method and compositions |
| 02/25/2009 | EP2026806A2 Use of vx-702 for treating rheumatoid arthritis |
| 02/25/2009 | EP2026805A1 Pharmaceutical combinations of diazole derivatives for cancer treatment |
| 02/25/2009 | EP2026804A1 Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity |
| 02/25/2009 | EP2026803A2 Compositions of r(+) and s(-) pramipexole and methods of using the same |
| 02/25/2009 | EP2026802A2 Jnk inhibitors for treatment of skin diseases |
| 02/25/2009 | EP2026801A2 Method of treatment of hereditary hemochromatosis |
| 02/25/2009 | EP2026800A1 Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
| 02/25/2009 | EP2026799A2 Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such |
| 02/25/2009 | EP2026798A1 Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators |
| 02/25/2009 | EP2026797A2 Method for treating non-hodgkin's lymphoma |
| 02/25/2009 | EP2026796A2 Use of a vasopeptidase inhibitor for the treatment of pulmonary arterial hypertension |
| 02/25/2009 | EP2026795A2 Antimalarial therapy using a combination of synthetic artemisinin derivative and bisquinoline derivative |
| 02/25/2009 | EP2026794A1 Xanthone derivative for the treatment of muscular disorders |
| 02/25/2009 | EP2026793A2 Use of escitalopram for improving cognition |
| 02/25/2009 | EP2026792A2 Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia |
| 02/25/2009 | EP2026791A1 Maternal supplement |